MELLARIL-S
LOE ApproachingNDAORALSUSPENSION
Approved
Oct 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MELLARIL-S is an oral suspension small-molecule antipsychotic approved in 1978 for psychiatric indications. The specific mechanism of action and indicated conditions are not publicly detailed in available data. This legacy formulation represents a decades-old treatment option in the antipsychotic class.
LOE Approaching
Product approaching loss of exclusivity with low commercial momentum; brand teams are typically small and focused on managed care and institutional channels.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MELLARIL-S offers minimal career growth opportunity given its LOE-approaching status and near-zero linked job openings. Roles on this brand focus primarily on compliance, institutional relationships, and managed decline rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on MELLARIL-S at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.